TriCelX, ADCAN Pharma and DAS Holding plan UAE biotherapeutic joint venture

By AI, Created 1:46 PM UTC, June 04, 2026, /AGP/ – TriCelX, ADCAN Pharma and DAS Holding signed a memorandum of understanding to create TriCelX Arabia, a UAE-domiciled joint venture aimed at distributing and eventually manufacturing TriCelX biotherapeutics across the Gulf. The deal is tied to TriCelX’s FDA-cleared knee osteoarthritis program and a newly filed CTE study, both of which the companies say strengthen the regional commercial and government-procurement case.

Why it matters: - TriCelX Arabia would give the Gulf Cooperation Council a new channel for biotherapeutic products aimed at medical countermeasures and neurological injury. - The venture is designed to start with imports from Texas and later add manufacturing in Abu Dhabi, which could shorten supply lines for regional buyers. - The agreement links a UAE market-entry plan to TriCelX’s U.S. regulatory progress, including an FDA Study May Proceed clearance and a CTE IND filing.

What happened: - TriCelX, ADCAN Pharma and DAS Holding executed a tripartite memorandum of understanding to form TriCelX Arabia, LLC in the UAE. - The new entity is planned as a GCC distribution and manufacturing platform for TriCelX’s biotherapeutic portfolio. - The MOU was announced on May 26, 2026, in Frisco, Texas and Abu Dhabi, United Arab Emirates. - Definitive agreements are expected to be negotiated over the coming months.

The details: - The joint venture is planned in two phases. - Phase one would import and distribute products from TriCelX’s FDA-registered facility in Frisco, Texas. - Phase two would establish a dedicated regional manufacturing center at ADCAN Pharma’s Abu Dhabi premises. - TriCelX says the venture is anchored to the first biotherapeutic platform IND in chronic traumatic encephalopathy filed since the December 2024 Blast Overpressure Safety Act. - TriCelX submitted the XytriX CTE Phase 1/2 IND on May 18, 2026, to FDA CBER’s Office of Tissues and Advanced Therapies. - The filing included requests for RMAT and Breakthrough Therapy Designation. - The CTE program uses the same drug substance as XytriX Knee Osteoarthritis, which received Study May Proceed status on April 22, 2026. - TriCelX says its federal engagement spans USAMMDA, U.S. Special Operations Command, BARDA under Project BioShield, CDMRP’s TBI Research Program, the National Intrepid Center of Excellence and AFRRI. - The company says the same FDA-reviewed platform will underpin regional distribution decisions for ADCAN, DAS and GCC procurement authorities. - Beyond CTE, TriCelX positions the XytriX platform for acute radiation syndrome, blast traumatic brain injury and combined-injury wounds. - TriCelX says no FDA-approved medical countermeasure currently covers those three domains. - The company says ADCAN could host cryogenic biorepository operations in Abu Dhabi. - DAS would serve as the strategic counterparty for government engagement across the GCC, MENA and adjacent markets. - Each GCC member state is described as an independent sovereign procurement opportunity.

Between the lines: - The MOU appears to pair a commercial distribution plan with a government procurement strategy. - TriCelX is using U.S. regulatory milestones to support credibility with regional health authorities and defense-related buyers. - The structure suggests the partners want local manufacturing optionality before broader GCC expansion. - The comments also frame XytriX as a platform technology rather than a single-indication treatment.

What’s next: - The parties will negotiate definitive agreements. - The companies still need U.S., UAE and other GCC regulatory approvals before any full-scale rollout. - FDA review remains underway for the RMAT and Breakthrough Therapy Designation requests. - The MOU is not binding except for any provisions expressly stated within it. - TriCelX says future activity could include Abu Dhabi manufacturing, regional distribution and broader government engagement across the Gulf.

The bottom line: - TriCelX is trying to turn its U.S. clinical and regulatory progress into a UAE-based commercial and manufacturing foothold for the GCC.